FHTX 241220 7.50C (FHTX241220C7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

FHTX241220C7500

Watchlist

0.75
-0.15-16.67%

15min DelayClose Nov 19 15:51 ET

0.75High0.75Low

Intraday

5D
Daily

News

Foghorn Therapeutics (FHTX) Collaborates With Eli Lilly and Surpasses Q3 Expectations
TipRanksNov 13 05:47 ET
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
GlobeNewswireNov 12 07:54 ET
Express News | Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
BenzingaNov 5 15:51 ET
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
Moomoo NewsNov 5 06:36 ET · Ratings
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
Moomoo NewsNov 4 19:33 ET · Ratings
TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
TipRanksNov 4 19:16 ET · Ratings

Comments

Bigmoney Dreamer

Oct 14 15:04

$Foghorn Therapeutics (FHTX.US)$ P/L= -25% in 22/23 days

Bigmoney Dreamer

Sep 25 15:23

Share Your Profit/Loss

Bigmoney Dreamer

Sep 17 16:53

$Foghorn Therapeutics (FHTX.US)$ testing 🧪🎯📈13$+

Jaguar8

May 20 08:54

$Foghorn Therapeutics (FHTX.US)$
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

Trytosaveabit

Apr 9 15:59

Update! Watching

$Foghorn Therapeutics (FHTX.US)$ Foghorn Therapeutics Inc. is set to share updates on its cancer research pipeline during a conference call and webcast on April 9, 2024, coinciding with the AACR Annual Meeting. The company will outline progress in its preclinical trials, including the development of promising new inhibitors and degraders, with the intention of engaging with investors about these advancements. These forward-looking statements, while offering insights into potential...